Redefining immune cell therapy through circularity

Syn-Gen™ integrates artificial intelligence with molecular modeling to rationally design circular RNA sequences that achieve optimal translation, minimal immunogenicity, and precise control of expression duration.
This platform transforms RNA design from trial-and-error into a data-driven, programmable process—accelerating therapeutic development across multiple disease targets.

Syn-O™ leverages a newly discovered  Group I intron–based PIE mechanism to achieve high-efficiency circularization with simplified purification.
This next-generation RNA circularization system features enhanced catalytic activity and sequence flexibility, enabling rapid adaptation for diverse therapeutic constructs and providing a robust backbone for all BiosynRNA circRNA products.

Syn-TX™ employs a modular lipid nanoparticle (LNP) and protein-fusion architecture to achieve cell-specific delivery of circRNA payloads.
This next-generation delivery system enables in vivo applications such as CAR-T and immune-modulatory therapies, expanding the boundaries of RNA medicine beyond conventional ex vivo approaches.

Syn-Mega™ introduces a proprietary enzymatic and FPLC-coupled purification workflow that enables large-scale production of ultra-pure circRNA with exceptional consistency and yield.
By bridging research-grade synthesis and industrial-scale manufacturing, it sets a new standard for clinical-ready RNA therapeutics.